FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287

D

Transaction(s)

69,571

(Instr. 4)

0.5

Estimated average burden hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	.ioi1 1(b).			1 1100		tion 30(h) of the						•						
1. Name and Address of Reporting Person* <u>Harwood Charles C Jr</u>						2. Issuer Name and Ticker or Trading Symbol Organogenesis Holdings Inc. [ORGO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O AVISTA HEALTHCARE PUBLIC ACQUISITION				3. Date of Earliest Transaction (Month/Day/Year) 12/10/2018								Officer (give title Other (spec below) below)						
CORP. 65 EAST 55TH STREET, 18TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NEW YORK NY 10022											X	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)															
		Та	ble I - Non	-Deriva	ative Se	ecurities Ac	quired	, Disp	osed c	of, o	r Bene	ficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/E						2A. Deemed Execution Date, if any (Month/Day/Year	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amoun Securities Beneficia Owned Fo	s lly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount		(A) or (D) Pri		Transacti	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
						curities Acqu ls, warrants							Owned					
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date irity or Exercise (Month/Day/Year) if any		Code (Instr.			Expiration	5. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	derivative Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

Date

Exercisable

(1)

Expiration

(1)

Title

Class A

Ordinary

Shares

Date

Class B

Ordinary

In connection with the closing of the Business Combination, the Issuer's name was changed to Organogenesis Holdings Inc.

/s/ Benjamin Silbert, Attorney-12/12/2018 in-Fact

** Signature of Reporting Person Date

Amount

Number

of Shares

243,896

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/10/2018

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code ν

 $D^{(2)}$

(A) (D)

243,896

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value \$0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value \$0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.

^{2. 243,896} Class B ordinary shares forfeited to the Issuer for no consideration prior to the closing of the Business Combination.